Lonza continues realization of long-term strategic initiatives
Advertisement
Lonza Group announced that the U.S. food and Drug Administration (FDA) has granted approval for a supplemental biologics License Application (sBLA) to Bristol-Myers Squibb Company, which includes the licensing of Lonza Biologics Inc. as their third-party manufacturing partner for the active pharmaceutical ingredient (abatacept) for ORENCIA®.
This manufacturing initiative was designed to support increased production capacity for rheumatoid arthritis indicated ORENCIA® (abatacept), which will enable Bristol-Myers Squibb to meet the anticipated long-term demand.